Amgen halts a PhI for FLT3 BiTE while resuming dosing on another

Amgen did a bit of a balancing act for its column of Phase I oncology programs during the latest quarterly update, as it disclosed that it’s resumed dosing for pavurutamab (AMG 710) but halted enrollment to a trial for AMG 427. Both were BiTE molecules with extended half lives. No…

...

Click to view original post